Ipamorelin

What it is (in plain language)
- It's the 'gentleman's peptide'. It stimulates the release of GH very effectively, but it does just that. Unlike GHRP-2 or 6, it doesn't cause hunger, it doesn't increase cortisol (stress hormone) and it doesn't increase prolactin. It's a purist way of raising GH while keeping the rest of the hormones in balance.

Why do you appear online so much
- It's a favourite for anti-ageing, skin improvement and long-term fat loss. It can be used for months on end with an almost non-existent side-effect profile, making it the ideal base for almost any longevity protocol.

How it is framed today (pragmatic view)
- 1) Evidence: Excellent clinical safety record in Phase II studies. 2) Purpose: Improved sleep quality, fat loss and rejuvenation. 3) Risk: Extremely low; the biggest 'risk' is the use of under-dosed products on the parallel market.

How to use this form
- Combine this reading with that of CJC-1295 No DAC to understand the famous 'combined protocol' that maximises results.

- Quick profile (curated by Subject 157)
- Class: Hormonal
- Status: Verified
- Use case: Hormonal
- Route: Injectable
- Tags: Injectable|GH|Recovery
- Half-life: ~2 Hours
- Start: Fast
- Duration: ~4-6 hours

- Mechanism (high level)
Selective agonist of the Ghrelin receptor (GHS-R1a). Stimulates the pulsatile release of HGH without affecting ACTH (Cortisol) or Prolactin. The 'cleanest' of the secretagogues.

- Evidence (what the literature covers)
RESEARCH RANGE (Non-prescriptive):
Common doses of 100mcg to 300mcg (night).
Level of Evidence: B.

- Safety and harm-reduction (non-prescriptive)
Risks: Slight headache (head rush) after injection.
Interactions: Unknown.

- References (anchors)
- Raun, K. (1998) - Ipamorelin selective GH secretagogue - https://doi.org/10.1530/eje.0.1390552 | PubMed:9820612
- Johansen, P. (1998) - Ipamorelin pharmacokinetics in rat - https://doi.org/10.1080/004982598238976

Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.